Puf-A and related compounds for treatment of retinopathies and sight-threatening ophthalmologic disorders
US9255130B2 · kind B2 · utility
1Cited by
0References
18Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 29, 2009 |
| Grant date | Feb 9, 2016 |
| Priority date | — |
| Expiry date | Jun 1, 2031 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2799/025
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Methods and compositions for treating retinal diseases comprising therapeutic amounts of a compound selected from a normal Puf-A gene product, an active polypeptide fragment thereof, an analog thereof or a peptidomimetic thereof. Vectors, including AAV vectors comprising the therapeutic compound are provided. Puf-A compositions suitable for subretinal, intravitreal, topical, subconjunctival, retrobulbar, periocular, suprachoroidal, or intraocular administration are provided. Methods for screening siRNA, RNAi and shRNA, small molecules and monoclonal antibodies that inhibit Puf-A target activity and reduce apoptosis are provided.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.